ATRA - Atara Biotherapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 5772.19M
Enterprise Value 3505.35M
Trailing P/E N/A
Forward P/E 1-2.86
PEG Ratio (5 yr expected) 1N/A
Price/Sales (ttm)N/A
Price/Book (mrq)2.42
Enterprise Value/Revenue 3N/A
Enterprise Value/EBITDA 6-1.74

Trading Information

Stock Price History

Beta (5Y Monthly) 2.29
52-Week Change 3-66.10%
S&P500 52-Week Change 321.38%
52 Week High 341.97
52 Week Low 310.38
50-Day Moving Average 315.08
200-Day Moving Average 314.12

Share Statistics

Avg Vol (3 month) 3644.46k
Avg Vol (10 day) 3379.02k
Shares Outstanding 554.15M
Float 28.6M
% Held by Insiders 11.96%
% Held by Institutions 1116.73%
Shares Short (Jan 30, 2020) 49.53M
Short Ratio (Jan 30, 2020) 413.62
Short % of Float (Jan 30, 2020) 429.40%
Short % of Shares Outstanding (Jan 30, 2020) 417.61%
Shares Short (prior month Dec 30, 2019) 49.76M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 30, 2018
Most Recent Quarter (mrq)Sep 29, 2019


Profit Margin 0.00%
Operating Margin (ttm)0.00%

Management Effectiveness

Return on Assets (ttm)-46.09%
Return on Equity (ttm)-81.08%

Income Statement

Revenue (ttm)N/A
Revenue Per Share (ttm)N/A
Quarterly Revenue Growth (yoy)N/A
Gross Profit (ttm)N/A
EBITDA -291.08M
Net Income Avi to Common (ttm)-292.49M
Diluted EPS (ttm)-6.05
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)282.92M
Total Cash Per Share (mrq)5.22
Total Debt (mrq)16.09M
Total Debt/Equity (mrq)5.05
Current Ratio (mrq)9.56
Book Value Per Share (mrq)5.88

Cash Flow Statement

Operating Cash Flow (ttm)-234.36M
Levered Free Cash Flow (ttm)-137.24M